Medscape & Paragon Therapeutics
2 shared events · Importance 3 · Last updated Sep 09, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
Medscape: Medscape reported the advisory committee's 9-3 vote that available evidence did not support efficacy of Deramiocel, which triggered a further 36% stock decline.
Paragon Therapeutics: Capricor is the central defendant in the securities fraud class action and the issuer whose Deramiocel BLA and statistical analysis plan changes are at the heart of the dispute. The litigation, the 64% stock drop, and the extended PDUFA date to November 22, 2026 leave its equity under heavy pressure and its regulatory path uncertain.
Aug 10, 2026 · 267 articles
Regulatory
Medscape: Reported on the advisory committee vote, providing details on the 9-3 decision.
Paragon Therapeutics: Central company facing regulatory rejection and multiple securities fraud lawsuits; stock collapsed over 78%.
Jul 27, 2026 · 305 articles
65
Medscape reported panel vote Paragon TherapeuticsCapricor Deramiocel...
60
Medscape reported panel vote Paragon TherapeuticsCapricor Deramiocel...
ERGEN INTELLIGENCE
Explore this relationship live
Track how Medscape and Paragon Therapeutics interact across events, view sentiment trends, and discover connected entities.
Open Dashboard